Información de la revista
Vol. 46. Núm. 6.
Páginas 345-347 (junio 2022)
Descargar PDF
Más opciones de artículo
Vol. 46. Núm. 6.
Páginas 345-347 (junio 2022)
Scientific Letter
Acceso a texto completo
Comparison of the clinical characteristics and mortality in acute respiratory distress syndrome due to COVID-19 versus due to Influenza A-H1N1pdm09
Comparación de las características clínicas y mortalidad debidas a Síndrome de Distrés Respiratorio Agudo debido a COVID-19 versus Influenza A-H1N1pdm09
C. Hernández-Cárdenas, G. Lugo-Goytia, D. Hernández-García, R. Pérez-Padilla
Autor para correspondencia

Corresponding author.
Respiratory Intensive Care Unit, Instituto Nacional de Enfermedades Respiratorias, Ismael Cosío Villegas, Mexico
Este artículo ha recibido
Información del artículo
Texto completo
Descargar PDF
Tablas (2)
Table 1. Demographic and clinical biomarkers and radiologic characteristics of the patients.
Table 2. Adjusted multivariate Cox proportional hazard models.
Mostrar másMostrar menos
Material adicional (1)
Texto completo
Dear Editor:

Severe pneumonia with the Influenza A-H1N1 virus was first reported in Mexico in April 2009,1 causing acute hypoxemic respiratory failure (AHRF), acute respiratory distress syndrome (ARDS), with an associated mortality ranging from 25.1–41% at different sites.2 The World Health Organization estimates that influenza affect 5–10% of adults and up to 20–30% of children, especially in immunosuppressed, at extremes of life, and in persons with comorbidities3 and causes approximately 390,000 deaths annually.

The outbreak of respiratory infection by the novel SARS-CoV-2 started in December 2019, in Wuhan (Hubei Province), China.4 From this city, the outbreak has been spreading to most countries worldwide in a severe pandemic.5 Up to December 3, 2020, the COVID-19 pandemic has given rise to a total of 62 million cases and 1.4 million deaths around the world,5 mainly due to respiratory failure, although a long list of complications in various organs and systems have been described. The COVID-19 disease is associated with severe pneumonia, AHRF, and ARDS, requiring intensive care and ventilatory assistance in up to 5% of cases, and with a reported mortality ranging from 30–60% (average 41%) at different sites.6

We wondered how case-fatality compares between ARDS-COVID-19 and ARDS-Influenza (A-H1N1), adjusting for known prognostic risk factors and obtained clinical chart information from consecutive patients with Influenza H1N1 (October 2019 to February 2020, prior to the COVID-10 outbreak) and patients with COVID-19 (March 2020 to October 2020). All patients had a positive viral RT-PCR test and fulfilled the 2012 Berlin Definition of Acute Respiratory Distress Syndrome. Patients with Influenza received Oseltamivir at 150mg daily for at least 5 days, and those with COVID-19 received various treatments that frequently included corticosteroids. The study was approved by the institutional ethics committee and informed consent was not required. The identity of the patients was protected.

Clinical and laboratory data were obtained upon admission and during the patients’ stay in the unit. High-resolution computed tomography (HRCT) was performed in all patients prior to admission to the respiratory intensive care unit (ICU). We calculated a bedside indicator of wasted ventilation, the ventilatory ratio (VR) as [1-minute ventilation (mL/min)×PaCO2 (mmHg)]/[predicted body weight×100×37.5)7 and the sequential organ failure assessment (SOFA) score, including PaO2/FIO2, platelets, bilirubin, creatinine, mean arterial pressure, and use of vasopressors. Glasgow score was the same as all the patients were sedated.

The information obtained was stored in an electronic database and the main outcome was survival from the ICU. Time to death was evaluated by a Cox proportional risk model, comparing the group with COVID-19 and that of the patients with influenza in non-adjusted models, and adjusting for age, gender, obesity, comorbidities, and biomarkers, and mechanical ventilation parameters.

Statistical analysis was performed with SPSS (version 21) and with STATA (version13.0) statistical software packages. Two-sided p values of <0.05 were considered statistically significant. Table 1 presents the main characteristics of patients with influenza (n=94) and with COVID-19 (n=147). Patients with influenza had a slightly higher body mass index (BMI), lactic dehydrogenase glucose, and SOFA score, and a higher proportion of individuals with obesity, fever, shortness of breath, muscle pain, and headache, with lower neutrophils. Patients with influenza arrived for care in a worse situation (Table 1), they were more hypotense, hypoxemic, requiring vasopressors more frequently, with a higher SOFA score. Those with COVID-19 had a higher crude ICU mortality (39% vs. 22%; Fisher exact test; p=0.007; log-rank test, p=0.01), lower respiratory compliance, and spent more days in the prone position. Table 2 analyzes a multivariate Cox proportional risk model, having as a dependent variable time to death in the ICU and, as an independent variable, the type of virus (COVID-19 vs. influenza) adjusted by age, sex, comorbidities, symptoms, laboratory results, and ventilatory parameters: COVID-19 patients had nearly 4 times more risk for death (OR=3.7; 95% CI=1.9–7.4) than patients with influenza (see figure in supplement). Additional variables associated with predicting mortality were the ventilatory ratio, the SOFA score, and BMI, whereas the number of days in prone ventilation was associated with reduced mortality with borderline statistical significance (p=0.055).

Table 1.

Demographic and clinical biomarkers and radiologic characteristics of the patients.

Patient characteristics  COVID-19 (n=147)  Influenza A-H1N1 (n=94)  p Value 
Age (years)  45±11  47±11  0.147 
Sex (M/F)  108/39  69/25  0.9 
BMI (kg/m232.3±6.3  34.4±7.5  0.021 
Onset of symptoms at hospital admission (days)  9.1±6.4  9.7±3.4  0.462 
Time in ICU (days)  15.3±12  15.9±10  0.687 
Mortality  58(39.4%)  21(22.3%)  0.005 
Fever  129(87.7%)  92(98%)  0.005 
Shortness of breath  125(85%)  94(100%)  <0.001 
Muscle pain  81(55.1%)  79(84%)  <0.001 
Headache  72(48.9%)  63(67%)  0.005 
Laboratory measures  Mean (±SD)     
White blood cell count/μl  10.9±4.6  9.1±4.7  0.004 
Lymphocyte count/μl  978±738  897±475  0.35 
Platelet count×103/μl  269±105  200±85  0.001 
Creatinine (0.7–1.2mg/dl)  1.28±1.17  1.37±1.36  0.61 
Lactic dehydrogenase (98–192UI)  468±184  712±366  0.001 
Glucose (mg/dl)  140±46  184±97  0.001 
Mean arterial pressure (mmHg)  80±10  70±<0.001 
Heart rate (beats/minute)  82±15  98±14  <0.001 
Use of Norepinephrine  55(37.4%)  56(59.5%)  <0.001 
PaO2/FiO2 (mmHg)  143±58  96±43  <0.001 
Tidal volume (ml)  406±54  395±62  0.14 
Respiratory rate (breaths/minute)  23±5.1  22±4.6  0.078 
PEEP (cm H2O)  11±12±0.001 
Plateau pressure (cm H2O)  28±26±0.01 
Compliance (ml/cm H2O)  26±12  30±0.002 
SOFA score  5.2±2.3  6.4±2.0  <0.001 
Ventilatory ratio  2.4±0.7  2.3±0.5  0.25 

Comorbidities were similar in both groups, except for chronic renal failure. All patients had lung opacities in a CT scanning of the thorax.

VR, ventilatory ratio. SOFA is the sequential organ failure assessment score (see text).

Table 2.

Adjusted multivariate Cox proportional hazard models.

HR  Adjusted 1HR (95% CI)  p  Adjusted 2HR (95% CI)  p 
COVID-19  5.1 (2.7–9.7)  <0.001  3.7 (1.9–7.4)  <0.001 
SOFA score  1.5 (1.4–1.7)  <0.001  1.3 (1.2–1.5)  <0.001 
Glucose (mg/dl)  1.005 (1.002–1.008)  0.002  1.0 (1.0–1.01)  0.02 
BMI (kg/m21.02 (0.99–1.05)  0.13  1.03(1.01–1.06)  0.03 
Days in prone position      0.94 (0.88–1.001)  0.055 
Ventilatory ratio      2.3 (1.5–3.4)  <0.001 

BMI, body mass index; VR, ventilatory ratio; HR, Hazard Ratio. SOFA is the sequential organ failure assessment score (see text). For the crude model (only COVID-19). Log likelihood -371, AIC 744, and BIC 748.

Patients with COVID-19 had a substantially higher lethality than those with influenza, despite both being in respiratory failure, both with ARDS, and after considering various predictors of death such as age, sex, some laboratory measurements, and ventilatory parameters, indicating in COVID-19 more severe lung damage and fewer possibilities of recovery. Influenza and COVID-19 may cause severe damage to the lungs, to other organs, and may cause death, and it is unknown whether this may be attributed to direct viral injury, to an exaggerated inflammatory reaction, or to the often mentioned cytokine storm8 in addition to personal susceptibility. Patients with COVID-19 have been compared with those with influenza and lacked a difference in cytokine levels.8 The findings of CT scanning overlap in the two infections,9 but patients with COVID-19 manifested vascular inflammation, and immunothrombosis10 to a higher degree than those with influenza. In addition, all of our patients received Oseltamivir, and an influenza vaccine of variable affectivity is available, although only a small proportion of our patients were vaccinated (5% of those arriving at the ICU). Most of our patients with COVID-19 received systemic corticosteroids, but an antiviral treatment and a vaccine were not yet available.

Our study shows limitations such as a small cohort of patients coming from a single high specialty center. However, it is prospective, and both cohorts were studied with few weeks of difference.

In conclusion, patients with respiratory failure and ARDS from COVID-19 treated in an ICU entertain a substantially increased risk of death compared with similar patients with Influenza A-H1N1, even adjusting for SOFA score and other relevant risk factors for mortality.

Author contributions

Authors 1 and 4 concept; Authors 2 and 3 data collection; Authors 2 and 4 statistical analysis; Autors1, 2 and 4 elaboration of the manuscript.

Appendix A
Supplementary data

The following are the supplementary data to this article:

R. Perez-Padilla, D. de la Rosa-Zamboni, S. Ponce de Leon, M. Hernandez, F. Quiñones-Falconi, E. Bautista, et al.
Pneumonia and respiratory failure from swine-origin influenza a (H1N1) in Mexico.
N Engl J Med, 361 (2009), pp. 680-689
A. Duggal, R. Pinto, G. Rubenfeld, R.A. Fowler.
Global variability in reported mortality for. critical illness during the 2009–10 influenza a(H1N1) pandemic: a systematic review and meta-regression to guide reporting of outcomes during disease outbreaks.
World Health Organization. Influenza (seasonal). Available from: https:// [01.06.20].
N. Chen, M. Zhou, X. Dong, J. Qu, F. Gong, Y. Han, et al.
Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.
Lancet, 395 (2020), pp. 507-513
World Health Organization.
Coronavirus disease (COVID-19) situation report.
R.A. Armstrong, A.D. Kane, T.M. Cook.
Outcomes from intensive care in patients with COVID19: a systematic review and meta-analysis of observational studies.
Anaesthesia, 75 (2020), pp. 13401349
P. Sinha, C.S. Calfee, J.R. Beitler, N. Soni, K. Ho, M.A. Matthay, et al.
Physiologic analysis and clinical performance of the ventilatory ratio in acute respiratory distress syndrome.
Am J Respir Crit Care Med, 199 (2019), pp. 333-341
P.A. Mudd, J.C. Crawford, J.S. Turner, A. Souquette, D. Reynolds, D. Bender, et al.
Distinct inflammatory profiles distinguish COVID-19 from influenza with limited contributions from cytokine storm.
S.O. Onigbinde, A.S. Ojo, L. Fleary, R. Hage.
Chest computed tomography findings in COVID-19 and influenza: a narrative review.
Biomed Res Int, 2020 (2020),
L. Nicolai, A. Leunig, S. Brambs, R. Kaiser, M. Joppich, M. Hoffknecht, et al.
Vascular neutrophilic inflammation and immunothrombosis distinguish severe COVID-19 from influenza pneumonia.
J Thromb Haemost, (2020),
Copyright © 2021. Elsevier España, S.L.U. y SEMICYUC
Medicina Intensiva
Opciones de artículo
Material suplementario
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?